KalVista Pharmaceuticals, Inc. (KALV) Estados Financieros e Histórico

KalVista Pharmaceuticals, Inc. (KALV) — Precio $27.00 HealthcareBiotechnology — NASDAQ

Últimos resultados publicados:

Estados financieros detallados de KalVista Pharmaceuticals, Inc. (KALV): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.

Resumen del Análisis

Márgenes de los últimos 12 meses: margen bruto 92.0%, margen operativo -120.8%, margen neto -119.4%.

Al precio actual de $27.00, KALV presenta beneficios negativos (P/E no significativo) y un ROE del -10.57%. La capitalización bursátil es de $1.4B.

Cuenta de Resultados (10 años)

Año2017201820192020202120222023202420252025
Ingresos$1.5M$8.4M$16.1M$12.7M00000$73.6M
Coste de Ventas$12666$18237$35021$40.2M$41.3M00$86.2M0$6.1M
Beneficio Bruto$1.5M$8.4M$16.1M-$27.5M-$41.3M00-$86.2M0$67.5M
I+D$12.7M$18.2M$35.0M$40.2M$41.3M$70.2M$80.3M$86.2M$71.7M$55.6M
Generales y Administrativos$11.2M$8.9M$10.9M$13.0M$16.6M$26.4M$30.6M$54.3M$116.3M$183.7M
Gastos Operativos$23.8M$27.1M$45.9M$13.0M$16.6M$96.6M$110.9M$54.3M$188.0M$239.4M
Beneficio Operativo-$22.3M-$18.7M-$29.8M-$40.5M-$57.9M-$96.6M-$110.9M-$140.4M-$188.0M-$171.8M
EBITDA-$22.3M-$18.5M-$29.4M-$40.0M-$57.4M-$80.7M-$94.4M-$134.3M-$173.3M-$150.6M
Gastos por Intereses00000000$5.8M$19.3M
Beneficio Antes de Impuestos-$18.6M-$15.8M-$20.7M-$29.0M-$46.2M-$82.3M-$92.9M-$135.1M-$180.1M-$171.4M
Impuestos00$124000$124000000-$8.5M$3.4M-$7.1M
Beneficio Neto-$18.6M-$15.8M-$20.8M-$29.1M-$46.2M-$82.3M-$92.9M-$126.6M-$183.4M-$164.3M
BPA$-1.92$-1.53$-1.38$-1.64$-2.33$-3.36$-3.33$-3.44$-3.69$-3.23
BPA Diluido$-1.92$-1.53$-1.38$-1.64$-2.33$-3.36$-3.33$-3.44$-3.69$-3.23
Acciones en Circulación (Diluidas)$9.7M$10.3M$15.1M$17.7M$19.1M$24.5M$27.9M$36.8M$49.7M$50.9M

Balance (10 años)

Año2017201820192020202120222023202420252025
Caja y Equivalentes$30.9M$51.1M$32.0M$15.8M$50.6M$30.7M$56.2M$31.8M$98.6M$229.3M
Inversiones a Corto00$68.8M$51.9M$198.3M$135.5M$93.1M$178.6M$89.0M$70.9M
Cuentas por Cobrar$2.5M$6.8M$11.3M$16.5M$11.7M$16.8M$18.6M$10.9M$15.1M$11.3M
Inventario000000000$3.4M
Activos Corrientes$34.2M$59.4M$115.5M$88.7M$264.3M$193.6M$172.3M$225.7M$241.7M$320.1M
Inmovilizado Material$97000$1.8M$2.4M$3.7M$7.5M$10.0M$10.8M$9.1M$2.0M$12.9M
Fondo de Comercio0000000000
Activos Intangibles0000000000
Activos Totales$34.3M$61.4M$118.1M$92.5M$272.0M$203.9M$183.2M$235.4M$250.8M$335.4M
Cuentas por Pagar$1.2M$1.4M$2.9M$1.7M$2.0M$3.6M$4.8M$9.1M$4.9M$8.3M
Deuda a Corto0000000000
Pasivos Corrientes$3.0M$23.2M$18.1M$7.7M$9.8M$11.6M$15.0M$22.8M$45.2M$57.4M
Deuda a Largo000000000$139.2M
Pasivos Totales$3.0M$34.1M$21.4M$8.8M$14.8M$18.8M$22.2M$28.8M$155.4M$338.1M
Reservas-$55.9M-$71.7M-$92.5M-$121.6M-$167.8M-$250.2M-$343.1M-$469.7M-$653.2M-$762.7M
Patrimonio Neto$31.3M$27.3M$96.7M$83.8M$257.2M$185.1M$161.0M$206.6M$95.4M-$2.7M
Deuda Total0$279000$54000$1.6M$5.9M$8.2M$8.2M$7.3M$6.3M$151.6M
Deuda Neta-$30.9M-$50.8M-$100.8M-$66.1M-$243.0M-$158.0M-$141.1M-$203.1M-$181.3M-$148.6M
Capital Circulante$31.2M$36.2M$97.5M$81.0M$254.5M$182.1M$157.3M$202.9M$196.5M$262.8M

Flujo de Caja (10 años)

Año2017201820192020202120222023202420252025
Beneficio Neto-$18.6M-$15.8M-$20.8M-$29.1M-$46.2M-$82.3M-$92.9M-$126.6M-$183.4M-$164.3M
Amortizaciones$40000$180000$378000$512000$537000$743000$718000$816000$941000$1.5M
Compensación en Acciones$394000$1.1M$3.0M$4.4M$7.1M0$9.9M$21.9M$12.3M0
Cambio en Capital Circulante-$4.2M$25.8M-$18.8M-$20.6M$8.3M-$12.3M$7.4M$15.2M$15.0M$954000
Flujo de Caja Operativo-$23.7M$10.6M-$36.4M-$44.8M-$30.2M-$78.1M-$75.3M-$89.2M-$152.9M-$81.6M
Inversiones (CapEx)-$74000-$1.4M-$1.1M-$220000-$82000-$931000-$1.2M-$443000-$434000-$1.7M
Adquisiciones$34.1M0$69.4M-$16.8M000000
Recompra de Acciones0000000000
Dividendos Pagados0000000000
Flujo de Caja Libre-$23.8M$9.1M-$37.4M-$45.0M-$30.3M-$79.1M-$76.5M-$89.7M-$153.3M-$83.3M

Crecimiento y Márgenes (10 años)

Año2017201820192020202120222023202420252025
Crecimiento Ingresos (anual)+458.1%+92.1%-21.3%-100.0%
Crecimiento Beneficio Neto (anual)+15.0%-31.7%-39.9%-58.8%-78.1%-12.8%-36.3%-44.9%+10.4%
Crecimiento BPA (anual)+20.3%+9.8%-18.8%-42.1%-44.2%+0.9%-3.3%-7.3%+12.5%
Cambio en Acciones (anual)+6.3%+46.1%+17.7%+7.6%+28.2%+14.0%+31.9%+35.0%+2.5%
Crecimiento FCF (anual)+138.4%-510.1%-20.3%+32.8%-161.3%+3.3%-17.3%-71.0%+45.7%
Margen Bruto99.2%99.8%99.8%-216.7%91.7%
Margen Operativo-1485.3%-222.8%-184.9%-319.4%-233.4%
Margen EBITDA-1482.6%-220.7%-182.6%-315.4%-204.6%
Margen Neto-1236.9%-188.3%-129.1%-229.4%-223.2%
Margen FCF-1582.2%108.8%-232.2%-354.9%-113.2%
Tasa Impositiva Efectiva-0.0%-0.0%-0.6%-0.4%-0.0%-0.0%-0.0%6.3%-1.9%4.2%

Datos por Acción (10 años)

Año2017201820192020202120222023202420252025
FCF por Acción$-2.45$0.88$-2.48$-2.54$-1.58$-3.23$-2.74$-2.44$-3.09$-1.64
Dividendo por Acción$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Acciones en Circulación (Básicas)$9.7M$10.3M$15.1M$17.7M$19.1M$24.5M$27.9M$36.8M$49.7M$50.9M

Qué mirar en Biotech

La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.

Rentabilidad

Rentabilidad sobre capital-1057.44%
Rentabilidad sobre capital invertido-46.81%
Rentabilidad sobre activos-41.28%
Margen bruto92.03%
Margen operativo-120.80%
Margen neto-119.44%

Salud financiera

Deuda / Patrimonio-104.83
Ratio corriente5.58

Ratios Clave (10 años)

Año2017201820192020202120222023202420252025
P/E-3.78-6.29-16.67-6.65-10.72-3.79-2.66-3.30-3.73-5.00
P/VC2.253.643.592.311.851.681.542.027.17-303.23
P/V46.8211.8321.5115.260.000.000.000.000.0011.17
Margen Bruto99.2%99.8%99.8%-216.7%0.0%0.0%0.0%0.0%0.0%91.7%
Margen Operativo-1485.3%-222.8%-184.9%-319.4%0.0%0.0%0.0%0.0%0.0%-233.4%
Margen Neto-1236.9%-188.3%-129.1%-229.4%0.0%0.0%0.0%0.0%0.0%-223.2%

Empresas relacionadas: COGT · KNSA · KRYS · KURA · LRMR · PTGX · SRRK

Explorar sector: Healthcare · Biotechnology

Más secciones de KALV: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos

Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones